For bacteremia, cure rates were 71 4% (15 of 21 subjects) compare

For bacteremia, cure rates were 71.4% (15 of 21 subjects) compared with 58.8% (10 of 17 subjects) for the ceftaroline and ceftriaxone groups, respectively (difference 12.6%, 95% CI −17.6% to 41.6%) [44]. At the late

follow-up visit (21–35 days after completion of therapy), relapse rates between the two treatment arms were similar in the CE population: 1.9% for the ceftaroline group and 1.2% for the ceftriaxone group (difference 0.7%, 95% CI −1.4% to 2.9%) [44]. Pooled post hoc exploratory analysis requested by the FDA to assess clinical improvement on day 4 of study therapy in participants with a confirmed bacterial pathogen at baseline showed a weighted difference in clinical response of 11.4% (95% CI 0.6–21.9%) in favor of ceftaroline 4-Hydroxytamoxifen [48]. Table 3 Summary of clinical cure rate at the test-of-cure visit in the co-primary analysis populations, FOCUS and CANVAS trials [12–15, 44, 47] Trial MITTE CE FOCUSa Clinical cure % (no. of cured/total no.) Differenceb (95% CI) Clinical cure % (no. of cured/total no.) Differenceb (95% CI) Ceftaroline Ceftriaxone Ceftaroline Ceftriaxone selleck kinase inhibitor 1 83.8 (244/291) 77.7 (233/300) 6.2 (−0.2, 12.6) 86.6 (194/224) 78.2 (183/234) 8.4 (1.4, 15.4) 2 81.3 (235/289) 75.5 (206/273) 5.9 (−1.0, 12.7) 82.1 (193/235) 77.2 (166/215) 4.9 (−2.5, 12.5) 1 and 2 82.6 (479/580) 76.6 (439/573) 6.0c

(1.4, 10.7) 84.3 (387/459) 77.7 (349/449) 6.7c (1.6, 11.8) Trial MITT CE CANVASa Clinical cure % (no. cured/total no.) Differenceb (95% CI) Ceftaroline Vanc/Az Ceftaroline Vanc/Az 1 86.6 (304/351) 85.6 (297/347) 1.0 (−4.2, 6.2) 91.1 (288/316) 93.3 (280/300) −2.2 (−6.6, 2.1) 2 85.1 (291/342) 85.5 (289/338) −0.4 (−5.8, 5.0) 92.2 (271/294)) 92.1 (269/292) 0.1 (−4.4, 4.5) 1 and 2 85.9 (595/693) 85.5 (586/685) 0.3 (−3.4, learn more 4.0) 91.6 (559/610) 92.7 (549/592) −1.1 (−4.2, 2.0) CE clinical efficacy population, CI confidence interval, MITT modified intent-to-treat population, MITTE modified intent-to-treat efficacy population, Vanc/Az vancomycin plus aztreonam combination aNon-inferiority margin was set at −10% for both FOCUS and CANVAS trials bTreatment

difference: cure rate ceftaroline − cure rate comparator group cWeighted treatment difference The CANVAS Trials The CANVAS (CeftAroliNe Versus vAncomycin in Skin and skin structure infections) 1 and 2 studies (NCT00424190 and NCT00423657, respectively) were multinational, multicenter, phase 3, double-masked, randomized, active comparator-controlled trials designed to evaluate the safety and efficacy of monotherapy with ceftaroline fosamil 600 mg IV every 12 h compared with a combination of vancomycin 1 g every 12 h plus aztreonam 1 g every 12 h IV for 5–14 days for the treatment of ABSSSI [14, 15, 45, 47] Dose adjustments for renal impairment by unblinded pharmacists were based on creatinine clearance and institutional guidelines.

Comments are closed.